In this video we focus on 6 cannabis primary markets in the Northern Hemisphere, namely the USA, Canada, UK, Israel, Germany and Switzerland. In the follow-up episodes regarding the Northern Hemisphere we will review cannabis developments in Portugal, Spain, Malta, Greece, Italy, Denmark, Ireland, France, Netherlands, Poland, Czech Republic. Jamaica and Thailand might be discussed in a more equatorial belt with Mexico and Colombia.
Regarding the USA (United States of America) we review split between states and what MSOs (multi-state operators) need to contend with while we wait for federal legalization. More than half of Americans have access to cannabis for responsible adult-use with 38 states and the District of Columbia enabling access to medical cannabis.
Regarding Canada we are seeing a push for developments related to access to additional psychedelics, which is an interesting market to track. The UK (United Kingdom) has been plagued by issues around patient access since initial positive reforms. It does seem that patient access is improving and CBD FMCG products are starting to become aligned with the Novel Food policies in the region requiring supporting product dossiers (FSA – Food Standards Agency). We also touch on GW Pharmaceuticals.
Regarding Israel with well over 100,000 medical patients it seems to be the only country where illicit cannabis is more expensive than legal approved cannabis. Israel saw very limited imports of cannabis for the first 6 months of 2021, however returned to being the largest importer of medicinal cannabis in the final 6 months of 2021. Naturally Israel has an extremely strong research base regarding cannabis.
The German cannabis market was touched on, with extensive discussion in a previous episode. https://youtu.be/uWSNcmUgx4Y Overview of Cannabis in Germany. This is a market with a high percentage +-65% of medical claims receiving a medical rebate from insurers. Most global cannabis cultivators are looking to migrate their GACP cultivation activities into EU GMP packing or extraction activities. Germany also has ambitions to be a major responsible adult-use market by 2024.
In the Swiss market we know that CBD flower (with a THC content under 1%) is unique and a fantastic model for how flower sales in Europe might progress. Switzerland is also mapping out a very interesting adult use market through its projects in the different cantons limited to 5,000 patients/users enrolled.
Look forward to more upcoming discussions.
Host: Jeff Verlinden
Mobile: +27 63 291 3334/Local 063 291 3334
Email: jeff@separations.co.za
Guest Speaker: Sibusiso Xaba
African Cannabis Advisory Group
Email: media@aca-g.com
Keywords in the interview: cannabis entrepreneurship, cannabis investment banking, CannaTech, cannabis Global Go, cannabis networking, medicinal cannabis, botanical medicine, responsible adult-use, global cannabis, international cannabis, cannabis licensed providers, special access schemes, NHS, novel foods, dossiers, cannabis equity markets, federal cannabis, taxation, imports, exports, cannabis headlines, Health Canada, MAPS (multidisciplinary association for psychedelic studies), UK conservative party, GW Pharmaceuticals, Theresa May, Sativex, Drug Master File, Marketing Authorization, access to unregistered cannabis medicine, magistral preparations, Uganda, Together Pharma, CUCMS, Control Union Cannabis, 295 pesticides, GC-MS, LC-MS, HPLC, cannabis testing, monograph, pharmaceutical businesses, adult use programs in Netherlands and Switzerland, Quality control, hemp, marijuana, dagga.
source
